# Genlight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genlight

- Industry: Medical Devices & Equipment
- Headquarters: Hangzhou, China
- Website: www.genlight.com
- Latest round: Series C (Apr 3, 2026)
- Investors on record: 16

## About

Based in Zhejiang, China and founded in 2020, Hangzhou Genlight Neurotech Co., Ltd., dba Genlight, is a medical device company working on cutting-edge technologies in the fields of neuroscience and neurosurgery. The company's founder, Peng Cao, Cao Peng, holds a bachelor’s degree in biomedical engineering from Xi’an Jiaotong University and a Ph.D. from the French National Graduate Institute and the University of Technology of Compiègne (UTC). In 2024, the company's epilepsy management "Epilcure" was selected as "Top 10 Brain-Computer Interface Industry Innovation Cases 2024".

In September 2026, Genlight closed a round of Series D funding from Cybernaut Investment Group, Ningbo State-owned Assets, Tianqi Hengsong Fund, and other investors.

Genlight focuses on developing innovative medical device solutions for drug-refractory epilepsy, brain tumors, Parkinson's disease, depression, etc. It also provides brain-computer interface scientific research services and total solutions based on neurocognition and diseases, including optogenetic scientific research equipment and consumables. Genlight's main products include "LaserRO", a MR-monitored semiconductor laser therapy system; "Epilcure", a close-loop responsive neurostimulation system for epilepsy management, detecting abnormal brain signals that may trigger seizures and automatically intervene with targeted stimulation; and "S-DEEP" brand intracranial depth electrodes and connection cables.

The company generates revenue from providing medical device solutions in the fields of neuroscience and neurosurgery.

Following the Series D funding, the company will continue to invest in commercialization and international expansion and further enhance its brain science data and algorithm platform.

## Funding rounds

- Series C, Apr 3, 2026 — CD Capital, SWSC Chongqing Investment Fund Management, Puxin Capital, Linchuang Capital, Yuhang Jinkong Capital, Hangzhou Gaoxin Technology Venture, Tailong VC, Yufu High-Quality Industry Fund
- Series B, Jan 17, 2022 — Qiming Venture Partners, China International Capital Corporation, Vision Plus Capital, CD Capital
- Series A, Apr 1, 2021 — Volcanics Venture, Greenriver Capital, Watson Capital, Yushan Partners
- Angel, Sep 1, 2020 — Haibang Venture, Yushan Partners

## Investors

- Haibang Venture — Angel
- Yushan Partners (https://capitalatlas.ai/funds/yushan-partners) — Angel, Series A
- Volcanics Venture (https://capitalatlas.ai/funds/volcanics-venture) — Series A
- Greenriver Capital (https://capitalatlas.ai/funds/greenriver-capital) — Series A
- Watson Capital (https://capitalatlas.ai/funds/watson-capital) — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Vision Plus Capital (https://capitalatlas.ai/funds/vision-plus-capital) — Series B
- CD Capital — Series B, Series C
- SWSC Chongqing Investment Fund Management (https://capitalatlas.ai/funds/swsc-chongqing-investment-fund-management) — Series C
- Puxin Capital (https://capitalatlas.ai/funds/puxin-capital) — Series C
- Linchuang Capital (https://capitalatlas.ai/funds/linchuang-capital) — Series C
- Yuhang Jinkong Capital (https://capitalatlas.ai/funds/yuhang-jinkong-capital) — Series C
- Hangzhou Gaoxin Technology Venture — Series C
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series C
- Yufu High-Quality Industry Fund (https://capitalatlas.ai/funds/yufu-high-quality-industry-fund) — Series C